natgillin/translations-raw huggingface dataset:
The pharmaceutical composition of claim 10, the vaccine of claim 23, or the peptide or polynucleotide of claim 24, wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, endometriosis, esophageal cancer, gastric cancer; diffused type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, ili peptid ili polinukleotid u skladu s patentnim zahtjevom 15, naznačen time što se rak bira iz skupine koju čine rak mokraćnog mjehura, rak dojke, rak vrata maternice, kolangiocelularni karcinom, CML, kolorektalni rak, endometrioza, rak jednjaka, rak želuca, rak želuca difuznog tipa, rak jetre, NSCLC, limfom, osteosarkom, rak jajnika, gušterače rak, rak prostate, bubrežni karcinom, SCLC, tumor mekog tkiva i tumor na testisima.
wherein the combination is selected from the group consisting of: a first nucleic acid sequence encoding a heavy chain of an antibody comprising heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 45-52, positions 70-77, and positions 116-125 of SEQ ID NO: 115, respectively; and a second nucleic acid sequence encoding light chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 49-53, positions 71-73, and positions 110-118 of SEQ ID NO: 122, respectively; 
Antitijelo prema patentnom zahtjevu 1 koje sadrži kombinaciju VH i VL od kojih svaki sadrži set regija koje određuju komplementarnost CDR1, CDR2 i CDR3 izabrane od slijedećih (i) do (ix): VH: CDR1: pozicije 45-52 SEQ ID NO: 115, CDR2: pozicije 70-77 SEQ ID NO: 115, CDR3: pozicije 116-125 SEQ ID NO: 115, VL: CDR1: pozicije 49-53 SEQ ID NO: 122, CDR2: pozicije 71-73 SEQ ID NO: 122, CDR3: pozicije 110-118 SEQ ID NO: 122,
The apparatus of any one of claims 11 to 18, wherein said carrier comprises a drive, said drive and said controller configured to advance said carrier unidirectionally away from said build surface. 
Uređaj prema bilo kojem od zahtjeva 11 do 18, naznačen time da navedeni nosač sadrži pogon, gdje su navedeni pogon i navedeni upravljač konfigurirani da pomiču navedeni nosač u jednom smjeru od navedene površine za oblikovanje.
To overcome this problem, EP 1 444 932 A1 proposes an extraction module, which is closed linearly (in contrast to a rotational closing movement) and which comprises means for detaching a capsule from the water injection means (needles). 
Da bi se svladao taj problem, EP 1444 932 A1 predlaže modul za ekstrakciju koji se zatvara linearno (za razliku od rotacijskog kretanja kod zatvaranja) i koji sadržava sredstvo za odvajanje čahure od sredstva za injektiranje vode (igle),
The method of claim 1, wherein the anti-refill fitment is assembled into the interior passage of the neck in said step (c) such that an axial end of the fitment extends axially out of the container. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 9 do 12. naznačen time što se nastavak koji onemogućuje ponovno punjenje sklapa u unutarnjem prolazu grla u navedenom koraku (c). tako da se aksijalni kraj nastavka pruža aksijalno izvan spremnika.
The ET-743 content was within specifications (95%-105%). 
Sadržaj ET-743 je bio unutar specifikacija (95%-105%).
The reaction flask and solids were washed with 80mL EtOAc. 
Tikvica za rcakciju i krutina su bili isprani s 80 mL EtOAc.
An intermediate silicone tie coat applied over and to the layer comprising a polar thermoplastic polymer (iii), 
(iv) silikonski vežući međupremaz, koji sadrži vulkanizabilni silikon kojeg se primjenjuje preko i na sloj koji sadrži polarni termoplastični polimer (iii);
The method of claim 1, wherein each R1 is independently H, —COOR4, —CON(R4)2, or a nitric oxide donor group of the formula —X1—X2—X3; and R4 is H. 
je neovisno jedan od drugoga H, -COOR4, -CON(R4)2, ili skupina koja je donor dušikovog monoksida; i R4 je H; ili
The safety bow according to claim 1, wherein the child's chair comprises one or more side pieces, and when the first and second connecting members are detachably fastened to the side pieces of the chair and the third connecting member is detachably fixed to the seat plate of the chair, the arched crosspiece is arched in a horizontal plane. 
Uporaba sigurnosnog luka prema bilo kojem od zahtjeva 1 do 15, za dječji stolac, kao što je stolac sa pločom za sjedenje i pločom za noge koji se jednostavno namješta u različite položaje po visini i dubini, tako da ih se pomakne uiiz vodilica u bočnim elementima stolca, poželjno zajedno sa dječjim sigurnosnim pojasom.
X represents a single bond, an oxygen atom, a sulfur atom, a vinylene group, a phenylene group, or a divalent group derived from a thienyl, piperidinyl, or pyridyl group; 
X predstavlja jednostruku vezu, atom kisika, atom sumpora, skupinu vinilena, skupinu fenilena ili dvovalentnu skupinu dobivenu iz skupine tienila, piperidinila ili piridila;
A compound selected from: or a pharmaceutically acceptable salt thereof, or any combination of two or more thereof; for use in preventing and/or treating a lysosomal storage disorder in a patient at risk for developing or diagnosed with the same. 
H F OH CH ili njegova farmaceutski prihvatljiva sol, ili bilo koja kombinacija dva ili više; za upotrebu u prevenciji i/ili liječenju poremećaja lizosomskog nakupljanja kod pacijenta s rizikom za razvoj ili dijagnozom istog.
Compounds of the formula 1 as claimed in one or more of claims 1 to 23 for use in the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders. 
Spojevi formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, namijenjeni upotrebi u liječenju i/ili sprječavanju poremećaja metabolizma masnih kiselina i poremećaja upotrebe glukoze.
Experimental tests of forming capability have been carried out by comparison with cold rolled strips of the same thickness. 
Eksperimentalni testovi sposobnosti formiranja izvedeni su uspoređivanjem sa hladno valjanim trakama iste debljine.
Thus, the user can discharge the total content or metered dose of the metering chamber in more than one action. 
Tako, dakle, korisnik može isprazniti ukupni sadržaj ili odmjerenu dozu iz odmjerne komore u više djelovanja, a ne samo u jednom.
A compound according to claim 6, wherein when R2 is (vi), (viii), or (ix), and when R13 and R14, R13b and R14, or R13 and 14a, or R13b and 14a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring; then the cycloalkyl ring is a is C3-C4cycloalkyl ring. 
Spoj prema patentnom zahtjevu 1 ili 2, naznačen time da je piperidinski prsten vezan preko atoma ugljika. Spoj prema patentnom zahtjevu 7, naznačen time da je piperidinski prsten N-supstituiran cikloalkilom. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time da R13 i R14, zajedno sa atomima ugljika preko kojih su povezani, formiraju fuzionirani fenilni, tienilni, oksazolilni, pirdinilni ili (C3-C6)cikloalkilni prsten; i gdje fuzionirani fenilni, tienilni, pirolilni, oksazolilni, pirdinilni ili cikloalkilni prsten opcionalno supstituiraju 1 do 3 R20 skupine.
The orally dispersing tablet of claim 14, wherein the tablet comprises 0.05-0.3 mg budesonide. 
ODT sukladno patentnom zahtjevu 10, naznačena time, što ODT sadrži 0,05-0,3 mg flutikazona.
a water inlet (14) arranged for discharging water into the brewing space, and 
dovod (14) vode izveden radi pražnjenja vode u prostor za pripremu napitka, i
The rearrangements include, for instance, rearrangements of immunoglobulin genes or T-cell receptor (TCR) rearrangements; see also Table 1. 
U9;22)[BCR-ABL]; hiperdiploidnost ili trisomije kromosoma 4, 10 i 17; hipodiploidnost; pregradnje imunoglobulinskih gena; i pregradnje receptora T-stanica (TCR).
A method according to any of numbered embodiments 1 to 3, wherein the axes of the first and second rotors are arranged such that a line drawn from the axis of the first rotor to the axis of the second rotor makes an angle of from 0 to 20°, below the horizontal. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, pri čemu su osi prvog i drugog rotora raspoređene tako da linija koja se vuče od osi prvog rotora do osi drugog rotora pravi kut od 0 do 20", ispod vodoravne.
a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer, said outer layer comprising a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at about pH 5 or above, said inner layer comprising a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said third polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base, 
HR P20180965 T1 PATENTNI ZAHTJEVI Formulacija lijeka s produženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo pacijenta, pri čemu spomenuti pripravak sadrži: jezgro i prevlaku za jezgru, to jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski sloj i unutarnji sloj; pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
said operation platform houses said fuel tank, preferably said mobile fuel distribution station further comprises: 
navedena radna platforma sadrži navedeni spremnik goriva, gdje po mogućnosti navedena pokretna postaja za distribuciju goriva dodatno ima:
The antibody of any one of claims 1-5 wherein the amino acid sequence of said protein consists of the amino acid sequence according to SEQ ID NO: 2. 
Antitijelo iz bilo kojeg od patentnih zahtjeva 1-5 gdje se aminokiselinska sekvenca spomenutog proteina sastoji od aminokiselinske sekvence u skladu sa SEK ID BR: 2.
Power-limit reporting in a communication system using carrier aggregation 
IZVJEŠĆIVANJE OGRANIČENJA SNAGE U KOMUNIKACIJSKOM SUSTAVU KORISTEĆI AGREGACIJU PRIJENOSNIKA
wherein the at least one mRNA of component (a) and the at least one free mRNA of component (b) are identical to each other, and wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. 
Imunostimulacijski pripravak prema bilo kojem zahtjevu od 1 do 3, naznačen time da su barem jedna slobodna mRNK i barem jedna (m)RNK iz komponente adjuvanta međusobno identične.
The method according to claim 1, characterized in that the C-terminal part of the CH3-domain is selected from the amino acid sequences of SEQ ID NO: 1, 3, 4, 5, 6, 7, or 8. 
Nukleinska kiselina prema patentnom zahtjevu 1, naznačena time, da je navedena nukleinska kiselina koja kodira sekvencu aminokiseline iz C-terminalnog dijela CH3-domene imunoglobulina razreda IgG, odabrana iz skupine koju čine nukleinske kiseline iz ID BR.
More preferably, the feedstock contains at least 10%, even more preferably at least 30% and most preferably at least 50% caramel by weight of dry matter. 
Poželjnije, sirovina sadržava najmanje 10%, čak još poželjnije najmanje 30% i najpoželjnije najmanje 50% karamele po masi suhe tvari.
The eluent was evaporated to a solid to yield 270.7mg of crude coupled product of Formula 29 . 
Eluent je bio uparen do krutine, da bi se dobilo 270 mg sirovog spojenog produkta formule 29.
The crystalline polymorph according to claim 1, wherein the polymorph exhibits a Raman spectrum having characteristic peaks at about- 3098, 1335 and 2237 cm-1. 
Kristalni polimorf u skladu s patentnim zahtjevom 1, naznačen time, da polimorf pokazuje Ramanov spektar s karakterističnim vrhovima na oko - 3098, 1335 i 2237 cm-1.
is selected from 
R* se bira između otoki
An isolated peptide of up to 50 consecutive amino acid residues of SEQ ID NO: 1, which comprise the sequence of SEQ ID NO: 6. 
Izolirani peptid od najviše 25 uzastopnih aminokiselinskih ostataka sa SEQ ID NO:1, koji sadrži sekvencu SEQ ID NO:6.
D is a drug moiety of the following formula (II): wherein: 
D je dio lijeka sljedeće formule (II): š Å
In some additional embodiments, the subject is a mouse. 
(iv) spomenuti subjekt je odrasla osoba ili mlada osoba.
Use of a suspension concentrate according to any of the above claims 1 to 9, for the treatment of a fungicidal disease on crops or ornamental plants; preferably for the treatment of scab on apples. 
Uporaba koncentrata otopine u skladu s bilo kojim od prethodno navedenih patentnih zahtjeva 1 do 11, za tretiranje gljivičnih bolesti na usjevima ili ukrasnim biljkama. Uporaba u skladu s patentnim zahtjevom 12, za tretiranje krastavosti na jabukama.
A composition of any one of claims 1 to 3, wherein said composition comprises at least one of the following combinations of compounds: carbetapentane and rilmenidine, baclofen and acamprosate, 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 3, naznačen time što sadrži najmanje jednu od sljedećih kombinacija lijekova:
A compound of formula I: wherein A is NH2 or OH; and B is H or NH2; or pharmaceutically acceptable salt or hydrate thereof, for use in the inhibition of a RNA viral polymerase. 
[image] pri čemu A je NH2; i B je H; ili njegova farmaceutski prihvatljiva sol ili hidrat, namijenjen upotrebi u inhibiciji RNK viralne polimeraze kod subjekta, pri čemu je virusna RNK polimeraza:
g)—Stabilizing and levelling the milling machine with a stabilizing and levelling apparatus; 
stabiliziranje i izravnavanje glodalice (100) s uređajem za stabilizaciju i izravnavanje (400, 400a);
Use of a composition according to claim 1 for the manufacture of a medicament for the treatment or prevention of a condition ameliorated by increasing a blood GLP-1 level, wherein the condition ameliorated by increasing a blood GLP-1 level is selected from the group consisting of diabetes, a condition related to diabetes, myocardial infarction, learning impairment, memory impairment, and a neurodegenerative disorder; or wherein the condition ameliorated by increasing a blood GLP-1 level is a neurodegenerative disorder selected from the group consisting of excitotoxic brain damage caused by severe epileptic seizures, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion-associated disease, stroke, motor-neuron disease, learning or memory impairment, traumatic brain injury, spinal cord injury, and peripheral neuropathy. 
Uporaba pripravka u skladu sa zahtjevom 1, naznačena time, da se koristi za izradu lijeka za liječenje ili prevenciju stanja koja se poboljšavaju povećanjem nivoa GLP-1 u krvi, pri čemu je stanje koje se može poboljšati povećanjem nivoa GLP-1 u krvi izabrano iz skupine koju čine dijabetes, stanje povezano s dijabetesom, srčani infarkt, smanjeno pamćenje, smanjeno učenje i neurodegenerativni poremećaj; ili pri čemu je stanje koje se može poboljšati povećanjem nivoa GLP-I u krvi je neurodegenerativni poremećaj izabran iz skupine koju čine ekscitoksično oštećenje mozga uzrokovano jakim epileptičkim događajima, Alzheimer-ova bolest, Parkinson-ova bolest, Huntington-ova bolest, bolest povezana s prionom, udar, motoričko-neuronska bolest, smanjeno učenje ili pamćenje, traumatsko oštećenje mozga, oštećenje leđne moždine i periferna neuropatija.
A polymorph of the hydrochloride salt of d9-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol having the structural formula: wherein said polymorph exhibits high-intensity diffraction peaks at diffraction angles (2θ) of 6.683, 10.201, 13.441, 15.517, 18.198, 19.719, 20.258, 21.68, 22.668, 25.543, 28.022, and 35.02 in X-ray powder diffraction analysis. 
Polimorf hidrokloridne soli d9-1-[2-dimetilamino-1-(4-metoksifenil)etil]cikloheksanol-hidroklorida sa strukturnom formulom: [image], naznačen time što navedeni polimorf pokazuje difrakcijske maksimume visokog intenziteta pod difrakcijskim kutevima (2θ) od 6,683, 10,201, 13,441, 15,517, 18,198, 19,719, 20,258, 21,68, 22,658, 25,543, 28,022, te 35,02 u analizi difrakcije rendgenskih zraka na prahu.
The methods for these tests are described more in detail in: Mitchell, J.R. 
Te su metode potanko opisane u: Mitchell, J.R.
o is an integer from 0 to 3 inclusive; and p is an integer from 0 to 5 inclusive; 
je -CO2RJ; RJ je C1-6alifat; o je cijeli broj od 0 do 3 uključivo; a p je 1.
EP2005/000400 (application number). 
(86) Broj međunarodne prijave:
The crude product was re-crystallized from EtOH/water. 
Sirovi, čvrsti produkt ponovno rekristalizira iz FLOH/vode.
Compounds of the formula (2a) wherein R1, R2 and X are as defined in formula (1) and L is a leaving group such as halogen, provided that when R1 is benzyl, X is oxygen, R2 is methyl then L is not chlorine or when R1 is benzyl, X is a bond, R2 is propyl then L is not chlorine, represent a further aspect of the invention. 
L < (2a) naznačen time da R!, R*i X su kako je definirano u formuli (1) iz zahtjeva 1 i L je izlazna skupina, uz uvjet da kada R' je benzil, X je kisik, R? je metil tada L nije klor ili kada R! je benzil, X je veza, R? je propil tada L nije klor.
The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises tenofovir disoproxil fumarate. 
Farmaceutski sastav prema patentnom zahtjevu 7, koji sadrži kombinaciju spoja formule IIBb/tenofovir dizoproksil fumarat/atazanavir.
The method of claim 6, wherein the IL-22 Fc fusion protein comprises the amino acid sequence of SEQ ID NO:10. 
Fuzijski protein Fc IL-22 prema zahtjevu 1 ili 2, naznačen time, da poveznica obuhvaća aminokiselinsku sekvencu SKYGPP (SEQ ID NO:43) ili RVESKYGPP (SEQ ID NO:44).
obtaining from a subject and, optionally enriching or isolating and propagating, a population of lymphocytes or T-cells; 
osiguravanje populacije limfocita ili T stanica, dobivenih iz subjekta i, opcijski obogaćivanje ili izoliranje i razmnožavanje, populacije limfocita ili T stanica;
A method for treating a subject suffering from disease or condition selected from Alzheimer's disease (AD), Parkinson's disease, melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, sarcoma, gastrointestinal carcinoma, liver cancer, biliary tract carcinoma, bile duct carcinoma, colorectal cancer, lung cancer, gallbladder cancer, breast cancer, pancreatic cancer, thyroid cancer, renal cancer, ovarian cancer, adrenocortical carcinoma, prostate cancer, lymphoma, neurofibromatosis, gastrointestinal stromal tumors, acute myeloid leukemia, myelodysplastic syndrome, leukemia, tumor angiogenesis, medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, pheochromocytoma, cancer-related pain and mastocytosis, said method comprising administering to the subject in need thereof an effective amount of a compound of structure: or a pharmaceutically acceptable salt thereof. 
Spoj kako je definiran u bilo kojem od zahtjeva 1-14, naznačen time da je za uporabu za liječenje melanoma, glioma, glioblastoma multiforme, pilocitnog astrocitoma, sarkoma, raka jetre, raka žučnog trakta, kolangiokarcinoma, raka debelog crijeva, raka pluća, raka žučnog mjehura, raka dojke, raka gušterače, raka štitnjače, raka bubrega, rak jajnika, raka nadbubrežne žlijezde, rak prostate, histiocitnog limfoma, neurofibromatoze, gastrointestinalnih stromalnih tumora, akutne mijeloidne leukemije, mijelodisplastičnog sindroma, leukemije, tumorske angiogeneze, medularnog karcinoma štitnjače, karcinoida, raka pluća malih stanica, Kaposijevog sarkoma, feokromocitoma, akutne boli, kronične boli, ili policistične bolesti bubrega. Farmaceutski pripravak naznačen time da sadrži spoj prema bilo kojem od zahtjeva 1-14, te farmaceutski prihvatljiv nosač ili pomoćno sredstvo.
or a pharmaceutically acceptable acid addition salt thereof. 
CI ili njegova farmaceutski prihvatljiva kisela adicijska sol.
W represents CH or N; Y represents CH or N; Z represents O, S or CH2; and n represents 0 or 1; 
W predstavlja CH ili N; Y predstavlja CH ili N; Z predstavlja O, S ili CH2; i n predstavlja 0 ili 1; ili sol takvoga spoja.
The study discussed above shows that Triptorelin 6-Month formulation is efficacious and safe in inducing chemical castration in patients with advanced prostate cancer. This new convenient formulation requires only 1 injection every 24 weeks, and shows comparable efficacy and safety with the marketed 1- and 3-Month formulations. Pharmaceutical composition made of microparticles for the slow release of an LHRH agonist at least during a period covering the 6th month after injection of said composition, said composition consisting of a single formulation of microparticles, wherein the microparticles are made of a copolymer of the PLGA type which incorporates said LHRH agonist in the form of a water insoluble peptide salt; said copolymer comprising at least 85 % (molar) of lactic acid and having an inherent viscosity between 0.1 and 0.4 dl/g, as measured in chloroform at 25 °C and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: 
Farmaceutski pripravak pripremljen od mikročestica za sporo oslobađanje LHRH agonista triptorelina, naznačeno time što taj pripravak sadrži prvu skupinu mikročestica 1 drugu skupinu mikročestica, gdje a) mikročestice te prve skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran taj LHRH agonist u obliku peptidne soli netopljive u vodi; taj kopolimer obuhvaća najmanje 85% (molarno) mliječne kiseline i ima inherentnu viskoznost između 0.5 i 0.9 dl/g, kako je mjereno u kloroformu na 25*C i pri koncentraciji polimera od 0.5 g/dL; b) mikročestice te druge skupine su napravljene od kopolimera PLGA tipa u kojem je inkorporiran taj LHRH agonist u obliku peptidne soli netopljive u vodi i koji obuhvaća količinu mliječne kiseline između 70% i 80% (molarno); mikročestice te prve i druge skupine dalje imaju raspodjelu čestica definiranu kako slijedi:
The tablet as in item 36, wherein said tablet does not crack under room temperature conditions within 24 hours of being released from a tablet press. 
Tableta kao što je zahtijevano u patentnom zahtjevu 9, pri čemu navedena tableta ne puca pod uvjetima sobne temperature unutar 24 sata od kako je oslobođena iz preše za tablete.
A representative PDE7 inhibitor, OM69 (compound 1) was tested against a panel of known Parkinson's disease targets to determine whether there was evidence of interaction with any of the tested targets. 
Inhibitor PDE7 za upotrebu u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da se koristi za liječenje poremećaja periodičnih pokreta udova pri spavanju (PLMS).
RD2 is selected from the group consisting of hydrogen, halogen, an optionally substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl and an optionally substituted C2-6 alkynyl; 
R'* je odabran iz skupine koja sadrži vodik, halogen, po izboru supstituiran C1.4 alkil, po izboru supstituiran C>. salkenil i po izboru supstituiran C2.4 alkinil;